Skip to main content
profile image
Selected Works of Reshma Mahtani
Presentation
Efficacy and Safety of Talazoparib versus Physician’s Choice of Chemotherapy (PCT) in US Patients with HER2-negative Germline BRCA1/2-mutated (gBRCA1/2mut) Locally Advanced/metastatic Breast Cancer (LA/MBC) in the EMBRACA Study
Northern New England Clinical Oncology Society. Annual Meeting (2019)
  • Reshma Mahtani, Baptist Health South Florida
Abstract
S. Diab; H.S. Rugo; L.A. Mina; S. Puhalla; N.L. Henry; N. Denduluri; D. Yardley. Y. Wang; L. Shahied Arruda; I.C. Tudor; E. Gauthier; A. Czibere; J.K. Litton; S.A. Hurvitz 
Disciplines
Publication Date
2019
Citation Information
Reshma Mahtani. "Efficacy and Safety of Talazoparib versus Physician’s Choice of Chemotherapy (PCT) in US Patients with HER2-negative Germline BRCA1/2-mutated (gBRCA1/2mut) Locally Advanced/metastatic Breast Cancer (LA/MBC) in the EMBRACA Study" Northern New England Clinical Oncology Society. Annual Meeting (2019)
Available at: http://works.bepress.com/reshma-mahtani/32/